House
Sign inCreate account
Drug lookup
Drug reference

tremelimumab

human IgG2 monoclonal antibody, CTLA-4 inhibitor, immune checkpoint inhibitor · anticancer, immunomodulator

human IgG2 monoclonal antibody, CTLA-4 inhibitor, immune checkpoint inhibitoranticancer, immunomodulator
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated

Mechanism

Tremelimumab is a human IgG2 monoclonal antibody that targets CTLA-4.

Indications

malignant mesothelioma (orphan drug designation, under investigation in clinical trials)

Related guidelines

Gastric premalignant conditions
ACG · Gastroenterology · 2025
Heart failure in diabetes
RSSDI · Cardiology · 2023
Diabetic foot — clinical management
MOHFW · Endocrinology · 2021
Antimicrobial resistance — clinical roadmap
MOHFW · Infectious Diseases · 2012
Sjögren's syndrome
EULAR · Rheumatology · 2025

Ask House about tremelimumab

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team